论文部分内容阅读
为了评价大剂量化疗(HDC)联合干细胞移植的作用,本文报告了用自体或异基因骨髓或外周血干细胞移植治疗小裂细胞淋巴瘤(SCCL)的结果。 1985年8月至1996年12月间51例复发或难治的SCCL患者接受了HDC±TBI联合ABMT(36例)或Allo-BMT(15例)。这些患者在准备做ABMT前骨髓活检未发现显微镜下浸润。预处理方案:Vp16 1800mg/M~2d-7,CTX 50mg/kg d-6～-4,加TBI。如果不适合给TBI,则给CBV方案:CTX 1800mg/M~2d-6
To evaluate the effect of high-dose chemotherapy (HDC) combined with stem cell transplantation, the results of the treatment of small-cell lymphoma (SCCL) with autologous or allogeneic bone marrow or peripheral blood stem cell transplantation were reported. Between August 1985 and December 1996, 51 patients with relapsed or refractory SCCL received HDC ± TBI combined with ABMT (36 patients) or Allo-BMT (15 patients). These patients did not find microscopic infiltration prior to preparation for ABMT bone marrow biopsy. Pretreatment program: Vp16 1800mg/M~2d-7, CTX 50mg/kg d-6~-4, plus TBI. If not suitable for TBI, give CBV program: CTX 1800mg/M~2d-6